Ravi Paluri is an Oncology physician affiliated with Atrium Health Wake Forest Baptist. OpenAlex indexes 146 publications with 2,082 citations (h-index 17); ClinicalTrials.gov lists 4 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Medical Center Blvd
Winston Salem, NC 271571900
Telephone
336-716-2255Provider last certified this registry record 17 Jul 2020.
Clinical trials
- Neoadjuvant Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma
Sponsor: Wake Forest University Health Sciences
- Study of Amplitude-Modulated Radiofrequency Electromagnetic Fields in Metastatic Pancreatic Cancer
Sponsor: THERABIONIC INC.
- Study Of Intrabucally Administered Electromagnetic Fields and Regorafenib
Sponsor: Wake Forest University Health Sciences
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
7 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Exelixis Inc.Program year202518 payments$16,618openpaymentsdata.cms.gov ↗
- Partner Therapeutics, Inc.Program year202512 payments
- Ipsen Biopharmaceuticals, IncProgram year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Combination of dual JAK/HDAC inhibitor with regorafenib synergistically reduces tumor growth, metastasis, and regorafenib-induced toxicity in colorectal cancer
Journal of Experimental & Clinical Cancer Research
2024 - TGFβ in Pancreas and Colorectal Cancer: Opportunities to Overcome Therapeutic Resistance
Clinical Cancer Research
2024 - Mature MUC5AC Expression in Resected Pancreatic Ductal Adenocarcinoma Predicts Treatment Response and Outcomes
International Journal of Molecular Sciences
2024 - Predictive Value of MUC5AC Signature in Pancreatic Ductal Adenocarcinoma: A Hypothesis Based on Preclinical Evidence
International Journal of Molecular Sciences
2023
Similar KOLs
Other experts from the same institution or the same specialty.
David Herrington, MD
Atrium Health Wake Forest Baptist
Bruce Lessey, MD
Atrium Health Wake Forest Baptist
David Hurd, MD
Atrium Health Wake Forest Baptist
Kevin High, MD
Atrium Health Wake Forest Baptist
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”